Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUCCESSOR-2 mezigdomide plus carfilzomib and dexamethasone in relapsed or refractory multiple myeloma
NL-OMON60018Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mezigdomide, carfilzomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started Aug 2024; status: active, not recruiting.
02
Drugs
mezigdomidecarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON60018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60018.